Luvox returns with OCD indication

The FDA has approved Luvox (fluvoxamine maleate, from Jazz Pharmaceuticals and Solvay Pharmaceuticals) for the treatment of obsessive compulsive disorder (OCD). Luvox was previously approved and marketed in the United States prior to a request made by Solvay in 2002 to withdraw Luvox from the market due to the interpretation of data supporting the chemistry, manufacturing, and controls (CMC) section of the original New Drug Application submission.

For more information call (650) 496-3777 or visit www.jazzpharmaceuticals.com.